Monographie - Clonazepam - Stabilis 4.0

Viimeisin päivitys :
05/12/2025

Epilepsialääkkeet

Clonazepam

Injektioneste

Oraaliliuos

Stabilius liuoksessa

Stabilius seoksissa

Tekijät, jotka vaikuttavat stabiliuteen

Yhteensopivuus

Antotapa

Viitteet

pdf

Kemiallinen rakenne

Kauppanimi

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Clonazepamum	Puola
Kriadex	Meksiko
Ravotril	Chile
Rivotril	Espanja, Hollanti, Kolumbia, New Zealand, Puola, Ranska, Saksa, Sveitsi, Unkari, Yhdistyneet arabiemiirikunnat

Viitteet

Injektioneste

Viitteet : Clonazepam

	tyyppi	julkaisu
939	Lehti	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1189	Lehti	Nation RL, Hackett LP, Dusci LJ. Uptake of clonazepam by plastic intravenous infusion bags and administration sets. Am J Hosp Pharm 1983 ; 40: 1692-1693.
1246	Lehti	Hooymans PM, Janknegt R, Lohman JJHM. Comparison of clonazepam sorption to polyvinyl chloride-coated and polyethylene-coated tubings. Pharm Weekbl [Sci] 1990 ; 12: 188-189.
1508	Lehti	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
2115	Lehti	Schneider JJ, Good Ph, Ravenscroft PJ,. Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion. J Pain Symptom Manage 2006 ; 31, 6: 563-567.
2217	Lehti	Guchelaar H.J, Hartog M.E. De stabiliteit van clonazepaminjectievloeistof. Ziekenhuisfarmacie 1997 ; 13, 1: 21-23.
3184	Laboratorio	Hyaluronidase (Hyalase®) - Summary of Product characteristics. CP Pharmaceuticals 2005
3617	Laboratorio	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3728	Lehti	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3823	Lehti	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3976	Lehti	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4867	ilmoitus	Dazan D, Aït Taleb S, Laroyenne N, Hamam Y, Conreur L, Paoli-Lombardo R, Primas N, Lamy E, Castera-Ducros C, Curti C et al. Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie. CSH (SNPHPU) Congress sept 2024 2024
4972	Laboratorio	RIVOTRIL 1 mg/1 ml, solution à diluer injectable en ampoules - Résumé des caractéristiques du produit. CHEPLAPHARM ARZNEIMITTEL GMBH 2025

Mentions Légales